Dr. Rajeev Kumar, MD
Neurology (Neurology Physician)
701 E. Hampden Ave, Suite 510
Englewood, CO 80013
Who else practices at this address →
Arapahoe County includes primary care (8% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 250
Licensed in Colorado since 1998, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
TX license M1191 (first issued 2005; cancelled by request) · CO license 37158 (first issued 1998; active) · MN license 35436
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 250
- Services billed
- 52,084
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 57,801 | 63 |
| Established patient office or other outpatient visit, 40-54 minutes | 264 | 135 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 204 | 78 |
| Established patient office or other outpatient visit, 30-39 minutes | 195 | 117 |
| Established patient office or other outpatient visit, 20-29 minutes | 187 | 67 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 186 | 59 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 141 | 41 |
| Injection of chemical for paralysis of nerve muscles on side of face | 88 | 32 |
| New patient office or other outpatient visit, 60-74 minutes | 71 | 71 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 46 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Englewood, CO | 818 |
| Rasagiline Mesylate | 335 |
| Clonazepam Other prescribers in Englewood, CO | 326 |
| Carbidopa-Levodopa Er (carbidopa/levodopa) Other prescribers in Englewood, CO | 285 |
| Rytary (carbidopa/levodopa) Other prescribers in Englewood, CO | 266 |
| Amantadine (amantadine hcl) Other prescribers in Englewood, CO | 238 |
| Pramipexole Dihydrochloride (pramipexole di-hcl) Other prescribers in Englewood, CO | 189 |
| Venlafaxine Hcl Er (venlafaxine hcl) Other prescribers in Englewood, CO | 165 |
| Rivastigmine Other prescribers in Englewood, CO | 152 |
| Selegiline Hcl | 120 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 59 payments worth $9,870 in total to this clinician.
| AbbVie Inc. | $9,162 |
|---|---|
| Mdd US Operations, LLC | $174 |
| Neurocrine Biosciences, Inc. | $167 |
| Acadia Pharmaceuticals Inc | $114 |
| Merz Pharmaceuticals, LLC | $57.12 |
| Revance Therapeutics, Inc. | $51.10 |
| Abbott Laboratories | $44.22 |
| Medtronic, Inc. | $39.27 |
| Consulting Fee | $7,150 |
|---|---|
| Food and Beverage | $1,603 |
| Travel and Lodging | $1,117 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 23, 2025 | Consulting Fee | $7,150 |
| AbbVie Inc. Nov 8, 2025 | Travel and Lodging BOTOX · NEUROSCIENCE · travel to NEWPORT BEACH, CA · in-kind | $378 |
| AbbVie Inc. Nov 7, 2025 | Travel and Lodging BOTOX · NEUROSCIENCE · travel to NEWPORT BEACH, CA · in-kind | $195 |
| AbbVie Inc. Dec 23, 2025 | Travel and Lodging travel to ENGLEWOOD, CO · in-kind | $165 |
| AbbVie Inc. Nov 7, 2025 | Travel and Lodging BOTOX · NEUROSCIENCE · travel to NEWPORT BEACH, CA · in-kind | $126 |
| AbbVie Inc. Nov 8, 2025 | Travel and Lodging BOTOX · NEUROSCIENCE · travel to NEWPORT BEACH, CA · in-kind | $126 |
| AbbVie Inc. Nov 8, 2025 | Travel and Lodging BOTOX · NEUROSCIENCE · travel to NEWPORT BEACH, CA · in-kind | $86.40 |
| AbbVie Inc. Nov 8, 2025 | Travel and Lodging BOTOX · NEUROSCIENCE · travel to NEWPORT BEACH, CA · in-kind | $22.48 |
| AbbVie Inc. Nov 8, 2025 | Travel and Lodging BOTOX · NEUROSCIENCE · travel to NEWPORT BEACH, CA · in-kind | $17.98 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 25 industry-funded studies in 2025, from 9 companies. The companies reported $782,622 in research payments for these studies, mostly to the institutions running them.
- A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease
Genentech, Inc. - Phase II dose finding study in prodromal early manifest HD individuals
Genentech, Inc. - A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
Sage Therapeutics, LLC - A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
Sage Therapeutics, LLC - Phase II study in early stage Parkinson s Disease Patients
Roche Tcrc, Inc. - Fixed-Dose Trial in Early Parkinson's Disease (PD)
AbbVie Inc. · Completed · NCT04201093 - Ph2a of IZD334 in Parkinsons disease
Genentech, Inc. - A Study of Lu AF82422 in Participants With Multiple System Atrophy
H. Lundbeck A S · Active, not recruiting · NCT05104476 - Open-label Trial in Parkinson s Disease (PD) (TEMPO-4)
AbbVie Inc. - A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor
Sage Therapeutics, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.